Determining clinically important differences in health status measures: A general approach with illustration to the Health Utilities Index Mark II

PharmacoEconomics

Volumn 15, Issue 2, 1999, Pages 141-155

  Samsa, Greg ^a   Edelman, David ^a,b   Rothman, Margaret L ^c   Williams, G Rhys ^c   Lipscomb, Joseph ^a,d   Matchar, David ^a,b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DURHAM VA MEDICAL CENTER   (United States)

^c JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^d DUKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEALTH STATUS; HUMAN; MEDICAL LITERATURE; MEDICAL RESEARCH; PRIORITY JOURNAL; QUALITY CONTROL; QUALITY OF LIFE; REVIEW; STROKE;

CLINICAL TRIALS; CROSS-SECTIONAL STUDIES; HEALTH STATUS INDICATORS; HUMANS; LONGITUDINAL STUDIES; PILOT PROJECTS; QUALITY OF LIFE;

EID: 0032956065     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199915020-00003     Document Type: Review

References (34)

1. 1. Guyatt GH, Jaeschke RJ. Reassessing quality-of-life instruments in the evaluation of new drugs. Pharmacoeconomics 1997; 12 (6): 616-26
2. 2. McHorney CA, Ware JE, Lu JFR, et al. The MOS 36-item short-form health survey (SF-36): III. tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care 1994; 32: 40-66
3. 3. Torrance GW, Feeny DH, Furlong WJ, et al. Multiattribute utility function for a comprehensive health status classification system: health utilities index mark 2. Med Care 1996; 34: 702-22
4. 4. Guyatt G, Walter S, Normal G. Measuring change over time: assessing the usefulness of evaluative instruments. J Chronic Dis 1987; 40: 171-8
5. 5. Ware JE, Kosinski M, Keller SD. SF-36 physical and mental health summary scales: a user's manual. Boston (MA): The Health Institute New England Medical Center, 1994
6. 6. Deyo RA, Patrick DL. The significance of treatment effects: the clinical perspective. Med Care 1995; 33 (4): AS285-91
7. 7. Llewellyn-Thomas HA, Williams JI, et al. Using a trade-off technique to assess patients' treatment preferences for benign prostatic hyperplasia. Med Decis Making 1996; 16: 262-72
8. 8. Stewart AL, Greenfield S, Hays RD, et al. Functional status and well-being of patients with chronic conditions: results from the medical outcomes study. JAMA 1989; 262: 907-13
9. 9. Thompson MS, Read JL, Hutchings HC, et al. The cost effectiveness of auranofin: results of a randomized clinical trial. J Rheumatol 1988; 15: 35-42
10. 10. Juniper EF, Guyatt GH, Willan A, et al. Determining a minimal important change in a disease-specific quality of life questionnaire. J Clin Epidemol 1994; 47: 81-7
11. 11. Kazis LE, Anderson JJ, Meenan RS. Effect sizes for interpreting changes in health status. Med Care 1989; 27 Suppl. 3: S178-89
12. 12. Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale (NJ): Lawrence Erlbaum Assoc., 1988
13. 13. Beaton DE, Hogg-Johnson S, Bombardier C. Evaluating changes in health status: reliability and responsiveness of five generic health status measures in workers with musculoskeletal disorders. J Clin Epidemiol 1997; 50: 79-93
14. 14. Matchar DB, Samsa GP, Cohen SJ, et al. A practice improvement trial implemented within managed care organizations: rationale and design of the Managing Anticoagulation Services Trial (MAST). Med Care. In press
15. 15. Ware JE, Kosinski M, Bayliss MS, et al. Comparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: summary of results from the medical outcomes study. Med Care 1995; 33 (4): AS264-79
16. 16. Ware JE, Kosinski M, Keller SD. SF-12: how to score the SF-12 physical and mental health summary scales. Boston (MA): The Health Institute New England Medical Center, 1995
17. 17. Ware JE, Snow KK, Kosinski M, et al. SF-36 health survey manual and interpretation guide. Boston (MA): The Health Institute New England Medical Center, 1993
18. 18. McHorney CA, Ware JE, Raczek AE. The MOS 36-item short-form health survey (SF-36): psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993; 31: 247-63
19. 19. Johnson PA, Goldman L, Orav EJ, et al. Comparison of the medical outcomes study short-form 36-item health survey in black patients and white patients with acute chest pain. Med Care 1995; 33: 145-60
20. 20. Bergner M, Bobbitt RA, Carter WB, et al. The sickness impact profile: development and final revision of a health status measure. Med Care 1981; 19: 787-805
21. 21. Deyo RA, Diehr P, Patrick DL. Health status measures: statistics and strategies for evaluation. Control Clin Trials 1991; 12 Suppl. 4: 142S-58
22. 22. Fryback DG, Dasbach EJ, Klein R, et al. The beaver dam health outcomes study: initial catalog of health-state quality factors. Med Decis Making 1993; 13: 89-102
23. 23. Kaplan RM, Bush JW, Berry CC. Heallh status: types of validity and the index of well-being. Health Serv Res 1976; 11: 478-507
24. 24. Stucki G, Liang MH, Fossel AH, et al. Relative responsiveness of condition-specific and generic health status measures in degenerative spinal stenosis. J Clin Epidemiol 1997; 48: 1369-78
25. 25. Damiano AM, Steinberg EP, Cassard SD, et al. Comparison of generic versus disease-specific measures of functional impairment in patients with cataract. Med Care 1995; 33 (4): AS120-30
26. 26. Weinberger M, Kirkman MS, Samsa GP, et al. The relationship between glycemic control and health-related quality of life in patients with non-insulin-dependent diabetes mellitus. Med Care 1994; 32: 1173-81
27. 27. Bergner M, Hudson LD, Conrad DA, et al. The cost and efficacy of home care for patients with chronic lung disease. Med Care 1988; 26: 566-79
28. 28. Deyo RA, Diehl AK, Rosenthal M. How many days of bed rest for acute low back pain? A randomized clinical trial. N Engl J Med 1986; 315: 1064-70
29. 29. Grotta J, for the US and Canadian Lubeluzole Ischemic Stroke Study Group. Lubeluzole treatment of acute ischemic stroke. Stroke 1997; 28: 2338-46
30. 30. Parmigiani G, Samsa GP, Ancukiewicz M, et al. Assessing uncertainty in cost-effectiveness analysis: application to a complex decision model. Med Decis Making 1997; 17: 390-401
31. 31. Weinstein MC, Stason WB. Hypertension: a policy perspective. Cambridge (MA): Harvard University Press, 1976
32. 32. Guyatt GH, Juniper EL, Walter SD, et al. Interpreting treatment effects in randomised trials. BMJ 1998; 316: 690-3
33. 33. McHorney CA. Generic health measurement: past accomplishments and a measurement paradigm for the 21st century. Ann Intern Med 1997; 127: 743-50
34. 34. Revicki DA, Allen H, Bungay K, et al. Responsiveness and calibration of the general well-being adjustment scale in patients with hypertension. J Clin Epidemiol 1994; 47: 1333-42